Please do your own research and don't treat this as advice, however please note this drug has received a blockbuster status.
Blockbuster status is defined as a drug that has a mass market appeal and that could earn over $1bn in sales p.a.
This is no small feat, so Eweezy I think you are wrong in that should it pass this phase 2b trial, the stock should go up a lot more.
If it fails, then yes it will plummet but based on real word evidence from TGA patients, this seems like a slim chance of failure.
Fifty One Capital updated report, page-66
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.050(15.4%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 37.5¢ | 34.0¢ | $980.3K | 2.746M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 34001 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 47595 | 6 |
View Market Depth
| Last trade - 11.39am 25/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
